SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its Snapdragon Ride Pilot system launching in BMW's iX3, highlighting increased automotive revenue and a push into ADAS. The community is discussing the potential for this and upcoming Snapdragon Summit announcements to drive the stock higher, with some eyeing a move towards long-term resistance levels. Bullish sentiment is fueled by Qualcomm's attractive valuation compared to its peers.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid discussions around rare earth elements and a recent deal with Australia, potentially positioning the company to benefit from efforts to reduce reliance on China. Community members are actively debating the impact of this deal, analyzing options flow, and speculating on potential catalysts such as government contracts, with some expressing concerns about dilution. Technical analysis and trading strategies are also being heavily discussed, with many participants closely watching for key price levels.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid discussions about a potential acquisition of Larvotto Resources and its impact on the company's valuation. The community is weighing the potential benefits of the deal against concerns about share dilution, while also debating the significance of U.S.-China trade relations and antimony's role as a critical mineral independent of rare earth dynamics.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings (CLIK) is trending due to renewed trading momentum following a report of strong revenue growth, sparking discussions of a potential short squeeze given its low float. The community is weighing the impact of insider ownership and potential for high volatility. Some traders are highlighting the stock's potential for significant gains, while others caution about its history and risk of dilution.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending as the community rallies around its real-world asset, Cocky Wings LLC, a food truck business that fuels buybacks. Discussions highlight the project's unique MemeFi ecosystem on Cardano, with many flocking to its arena for passive rewards and revenue-generating potential. The partnership with $SNEK energy drinks is also generating excitement.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential in the menin inhibitor space alongside competitor KURA, weighing its two FDA-approved drugs and revenue against KURA's upcoming PDUFA. Community members are highlighting SNDX's high short interest, potential buyout scenarios, and upcoming earnings as factors driving current interest. Some traders are debating the impact of FDA label expansion and a boxed warning on future growth.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as the stock plunges following a pause in clinical trials due to a patient developing liver problems, sparking discussions about the safety of gene editing and its impact on the sector. While some investors are concerned about the potential long-term implications, others view the overreaction as a buying opportunity, emphasizing the long-term potential of CRISPR technology and the company's pipeline. Community members are debating whether the trial pause is a temporary setback or a more serious issue, with some pointing to the patient's age and BMI as contributing factors.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG Crypto is trending as the community buzzes about passive income opportunities through holding and earning Solana rewards. Discussions highlight the project's ongoing development, including participation in a Solana hackathon, and the potential for transparent, community-driven growth within the DeFi space. Some users express skepticism, while others voice strong conviction in the project's long-term potential and unique reward system.

DZZ provides -2x the daily performance of futures contracts relating to gold. The notes index selects contracts based on the shape of the futures curve to minimize contango.

Deutsche Bank AG London - DB Gold Double Short ETN

PowerShares DB Gold Double Short ETN

DZZ is trending due to discussions around potential gains as a double short gold ETF, with community members pointing to gold's struggles and anticipating further downward movement. Some traders highlight technical indicators suggesting a possible squeeze, while others reference broader market conditions and their potential impact on gold prices. Overall, the sentiment leans towards DZZ benefiting from a bearish outlook on gold.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending due to a newly announced $800,000 order for drone components from Red Cat Holdings. The community is discussing the significance of this order, particularly the motors that will power Red Cat's FANG drones, and what it means for UMAC's position in the defense and government drone markets. Some are speculating about larger contracts on the horizon and the potential for further growth in the drone sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to Morgan Stanley, the acquisition provides positive read-through to Dyne.</li><li>Both Avidity and Dyne are advancing therapies for rare muscle diseases, myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.&nbsp;</li><li>Morgan Stanley’s $48 price target implies a potential 180% upside from DYN’s Friday closing price.&nbsp; &nbsp;</li></ul>Shares of Dyne Therapeutics Inc. (DYN) jumped 42% on Monday morning after Novartis (NVS) agreed to acquire the company’s key competitor Avidity Biosciences (RNA).According to Morgan Stanley, the acquisition provides positive read-through to Dyne, as reported by TheFly. Both Avidity and Dyne are advancing therapies for rare muscle diseases, myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD), and attempting targeted delivery of RNA into muscle.<h2 class="st-heading-2">Targeted RNA Delivery Platforms</h2>Avidity has demonstrated the successful targeted delivery of RNA into muscle with its Antibody Oligonucleotide Conjugate platform, which is part of the Novartis acquisition. Dyne has also developed its FORCE platform to develop therapeutics that address the root cause of disease and deliver functional improvement for people living with neuromuscular disorders.Morgan Stanley has kept an ‘Overweight’ rating and $48 price target on Dyne shares. The $48 price target implies a potential 180% upside to the stock’s closing price on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DYN">DYN stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/60;" src="data:image/png;base64,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" width="586" height="60"><figcaption>DYN's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Oct. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, opined that the current share value is too high.<stembedurl>https://stocktwits.com/FetchDog/message/633795771</stembedurl>Another sees the falling to about $20 later on Monday.<stembedurl>https://stocktwits.com/SpudZone/message/633818634</stembedurl>Novartis <a href="https://stocktwits.com/news-articles/markets/equity/why-avidity-biosciences-stock-is-jumping-over-43-in-premarket-today/cLG0dICR3Ma">announced</a> on Sunday that it will buy Avidity for $72 per share, following the separation of Avidity’s early-stage precision cardiology programs. The per share price implies a total equity value of $12 billion on a fully diluted basis. The transaction is expected to close in the first half of 2026.DYN stock is up 3% this year but is down about 21% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-records-nine-consecutive-months-of-sales-growth-in-september-thanks-to-major-bump-up-in-us-figures/cLG0atpR3MC">Toyota Records Nine Consecutive Months Of Sales Growth In September, Thanks To Major Bump Up In US Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis 

According to Morgan Stanley, the acquisition provides positive read-through to Dyne.

Equity

<ul class="summary-bullets"><li>While Dow Jones futures were up by 0.56% at the time of writing, the S&amp;P 500 futures rose 0.88%.</li><li>Asian markets ended Monday’s trading session on a positive note, with the KOSPI leading with gains of 2.5%.</li></ul>U.S. stocks appear set for a positive opening on Monday after trade tensions with China eased following a meeting with officials from the United States and China over the weekend.Treasury Secretary Scott Bessent and Trade Representative Jamieson Greer led the U.S. delegation for the fifth round of talks between the United States and China. “I think we’ve reached a substantial framework for the two leaders who will meet next Thursday,” Bessent said on ABC, following the meeting.President Donald Trump and his Chinese counterpart, President Xi Jinping, are scheduled to meet on Thursday.<h2 class="st-heading-2">Futures Trade Higher</h2>While Dow Jones futures were up by 0.56% at the time of writing, the S&amp;P 500 futures rose 0.88%, while the tech-heavy Nasdaq 100’s futures rose 1.33%. Futures of the Russell 2000 index gained 1.12%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was up by 0.85% at the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) gained 1.33% on Monday morning, and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) rose 0.54%. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bearish’ territory.<h2 class="st-heading-2">Asian Markets Positive</h2>Asian markets ended Monday’s trading session on a positive note, with the KOSPI leading with gains of 2.5%, followed by the Nikkei 225 index at 2.28%, and the TWSE Capitalization Weighted Stock index at 1.65%.The Shanghai Composite gained 1.17%, while the Hang Seng rose 1.01%.<h2 class="st-heading-2">Stocks To Watch</h2><ul><li>Nvidia Corp. (NVDA), Advanced Micro Devices Inc. (AMD): Shares of Nvidia and AMD rose nearly 3% in Monday’s pre-market trade amid easing trade tensions with China following the talks over the weekend.</li><li>MP Materials Corp. (MP): MP Materials shares declined nearly 5% pre-market after Bessent said he expected China to defer some of the curbs planned on rare earth exports, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/world/china/bessent-sounds-confident-note-after-trade-talks-with-china-f09d310d">report</a> by The Wall Street Journal. MP Materials is the biggest rare earth producer in the U.S.</li><li>Boeing Co. (BA): Boeing’s machinists in the St. Louis area will continue with their strike after rejecting a proposed contract for the fourth time. The Trump administration also announced that Malaysia and Cambodia will purchase some Boeing aircraft. Boeing shares were up 0.5% pre-market.</li><li>Avidity Biosciences Inc. (RNA): Avidity shares were up nearly 44% pre-market after Novartis AG (NVS) agreed to acquire the former for $12 billion.</li><li>Nucor Corp. (NUE), Bed Bath &amp; Beyond Inc. (BBBY), and NXP Semiconductors NV (NXPI) are among the companies scheduled to report their latest quarterly earnings on Monday.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-risk-drawdown-rising-us-equities-new-record-highs/cLGJvJDR3tl">Goldman Sachs Warns Risks Of A Drawdown Are Rising As US Equities Climb To Fresh Record Highs: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Rise As China Trade Tensions Ease: NVDA, MP, BA, RNA Among Stocks To Watch

While Dow Jones futures were up by 0.56% at the time of writing, the S&P 500 futures rose 0.88%.

NVDA, MP, BA, RNA Among Stocks To Watch

<ul class="summary-bullets"><li>Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.</li><li>The deal is expected to close in the first half of 2026.</li><li>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago.</li></ul>Avidity Biosciences, Inc. (RNA) shares&nbsp;soared over 43% in Monday’s early premarket session after the mid-cap biopharma focusing on developing RNA therapeutics called antibody oligonucleotide conjugates (AOC), announced a deal to be bought by Swiss pharma giant Novartis (NVS).<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences</a> stock has gained more than 60% this year.<h2 class="st-heading-2">The Novartis Deal Terms</h2>In a statement released on Sunday, Novartis said it would acquire San Diego-based Avidity Biosciences following the separation of the latter’s early-stage precision cardiology programs. The deal, approved by the boards of both companies, is valued at $72 per share in cash. This represented a 46% premium over RNA stock’s closing price of $49.15 on Friday.The total transaction value is $12 billion on a fully diluted basis. Avidity Biosciences currently boasts a market capitalization of $7.17 billion.Vas Narasimhan, CEO of Novartis, said, “Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”Before the merger's closing, Avidity will transfer its early-stage precision cardiology programs and collaborations to SpinCo, a wholly owned subsidiary of Avidity. Holders of Avidity common stock will receive a distribution of one share of SpinCo for every ten shares of Avidity they hold and/or a pro rata cash distribution of the proceeds received by Avidity before the closing if certain SpinCo assets are, or SpinCo itself is, sold to a third party.The deal is expected to close in the first half of 2026, subject to the completion of a spin-off or the sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.Novartis said the proposed acquisition raises the expected 2024-2029 sales growth from 5% to 6% on a compounded annual growth rate (CAGR) basis, representing a significant opportunity to deliver substantial shareholder returns over time.<h2 class="st-heading-2">What Retail’s Saying About The Buyout Deal</h2>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago. The message volume on the stream also improved to ‘extremely high.’&nbsp; Retail chatter spiked 6,100% over the 24 hours leading up to late Sunday.<figure class="image"><img style="aspect-ratio:620/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_27_at_6_02_00_AM_png_9d47ea362a.webp" alt="Screenshot 2025-10-27 at 6.02.00 AM.png" width="620" height="56"><figcaption>RNA sentiment and message volume as of 6 a.m. ET, Oct. 27 | source: Stocktwits</figcaption></figure>A bullish user noted that RNA traded at $5 two years ago and congratulated the believers.<stembedurl>https://stocktwits.com/Cutlass/message/633766787</stembedurl>Another user said they would cash out on Monday.<stembedurl>https://stocktwits.com/ure300/message/633760283</stembedurl>Earlier this month, Avidity Biosciences said it has completed a positive pre-Biologic License Application (BLA) meeting with the FDA regarding its delpacibart zotadirsen, an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy (DMD) who have gene mutations amenable to exon 44 skipping.&nbsp;The timing for the BLA submission was pushed back to the first quarter of 2026 from the previous guidance of year-end 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-rises-premarket-today-as-stock-closes-in-on-200-psychological-threshold/cLG0TBNR3Md">Palantir Rises Premarket Today As Stock Closes In On $200 Psychological Threshold: What’s Driving The Gains?</a>

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Why Avidity Biosciences Stock Is Jumping Over 40% In Premarket Today

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG PR Newswire SAN DIEGO, Oct. 26, 2025 Novartis to...

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported...

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, Oct. 16, 2025 SAN DIEGO, Oct. 16, 2025...

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA...

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-proposed-public-offering-of-common-stock-302553124.html">stated</a> that it intends to grant the underwriters an option to purchase up to an additional $75 million of shares, while adding that there can be no assurance as to whether or when the offering may be completed.The proceeds of the offering are expected to advance the development of the company’s three late-stage clinical programs, help build appropriate commercial inventory levels to support multiple potential launches, and expand its commercial infrastructure. The company also intends to progress research and development associated with its Antibody Oligonucleotide Conjugates platform and use the proceeds for working capital and general corporate purposes.Avidity had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30. It had stated in August that it expects to have sufficient funds for its operations through mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">RNA stock</a> rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1360/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_7_16_45_AM_png_8af84254fb.webp" alt="RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1360" height="122"><figcaption>RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Avidity stock has a good chance of hitting $100 in a year.<stembedurl>https://stocktwits.com/dgbio/message/628258214</stembedurl>The Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">reported</a> last month that Novartis made a takeover approach for Avidity, adding that the discussions were at an early stage and might not result in a deal.Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Bank of America raised its price target on Avidity to $56 from $54 on Thursday, while maintaining a ‘Buy’ rating on the shares. The firm pinned the price target hike on recent study results, which showed that treatment with Avidity’s Del-zota reversed disease progression in patients with DMD.RNA stock is up by about 60% this year and by about 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-cpi-report/chwN03BRdv4">Dow Futures Edge Higher As Wall Street Awaits Consumer Inflation Data: ORCL, OPEN, KLAR, ADBE Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Avidity Biosciences Stock Down 20% Pre-market Today?

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

RNA
Avidity Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNA News

RNAAvidity Biosciences Inc